Takeda Pharmaceutical (TAK) Profit After Tax (2017 - 2026)

Takeda Pharmaceutical's Profit After Tax history runs 10 years deep, the most recent figure standing at -$2.3 billion for Q1 2026.

• On a quarterly basis, Profit After Tax fell 388.33% year-over-year to -$2.3 billion in Q1 2026; TTM through Mar 2026 was -$692.2 million, a 131.98% decrease from a year earlier, with the FY2026 full-year figure at -$1.0 billion, down 242.35% from the prior year.
• Profit After Tax retreated to -$2.3 billion in Q1 2026 per TAK's latest filing, from -$669.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at $2.1 billion in Q3 2022 and bottomed at -$2.3 billion in Q1 2026.
• The 5-year median for Profit After Tax is $812.1 million (2022), against an average of $627.2 million.
• Across the five-year window, Profit After Tax jumped 395.46% in 2022 and tumbled 422.33% in 2024, its largest moves.
• Year by year, Profit After Tax stood at $843.4 million in 2022, then tumbled by 75.05% to $210.4 million in 2023, then slumped by 422.33% to -$678.2 million in 2024, then rose by 1.21% to -$669.9 million in 2025, then tumbled by 250.66% to -$2.3 billion in 2026.
• Per Business Quant, the three latest TAK Profit After Tax figures stand at -$2.3 billion (Q1 2026), -$669.9 million (Q4 2025), and $1.5 billion (Q3 2025).